ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adults.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Sensorimotor function as an early marker of cognitive decline and alzheimer's biomarker burden.GeroScience · 2026Article
- Performance of upper-arm capillary blood collection for Alzheimer's disease and central nervous system biomarkers: comparison of Tasso+ and venous plasma.medRxiv : the preprint server for health sciences · 2026Article
- Circulating Biomarkers of Neurodegeneration and All-Cause and Dementia-Specific Mortality.Neurology · 2026Article
- Grip strength modifies the association between blood-based alzheimer's biomarkers and cognitive function.GeroScience · 2026Article
- Plasma Aβ42/p-Tau217 ratio and p-Tau217 independently predict CSF-defined Alzheimer's disease pathology in a Brazilian admixed cohort.Frontiers in aging neuroscience · 2026Article
- Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers.Annals of neurology · 2025Article
- Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Population disparities in Alzheimer's disease: A systematic review of fluid and neuroimaging biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe relationship between Alzheimer's disease (AD) plasma biomarkers, and physical functioning (PF) across diverse races and ethnicities remains unclear. This study aims to explore this association in an ethno-racially diverse sample of cognitively unimpaired community-dwelling adults.
methodsData clinical examinations, neuropsychological tests, blood draws, and PF exams (Timed Up and Go [TUG] and Short Physical Performance Battery [SPPB]) were analyzed. Multivariable linear regressions assessed the association between PF and AD plasma biomarkers (amyloid beta [Aβ]40, Aβ42, total tau [t-tau], neurofiliament light chain [NfL]).
resultsThe sample (n = 2358; mean age 64.7 years; 65.9% female), was 20% African American, 41.9% non-Hispanic White, and 38.1% Hispanic. Findings indicate that worse PF is linked to higher biomarker levels (p < 0.05). Associations differed by race and ethnicity group. TUG time was associated (p < 0.05) with Aβ40, Aβ42, and tau among non-Hispanic Whites, whereas SPPB scores were associated (p < 0.05) with t-tau and NfL among African Americans. DISCUSSION: PF, ethnic/racial, and plasma AD biomarker data should be used to aid in developing risk profiles for neurodegenerative diseases. HIGHLIGHTS: Alzheimer's disease (AD) biomarkers are associated with physical functioning (PF) Ethno-racial variation exists in AD biomarker and PF associations Race and ethnicity should considered when assessing neurodegenerative disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.